The Drive to Discover. The Experience to Deliver.
Incyte's vision is to become a leading biopharmaceutical company by building a proprietary pipeline of novel small molecule drugs for serious unmet medical needs primarily in the area of oncology.
The field of oncology is evolving rapidly and transforming how cancer is and will be treated. With a growing pipeline that includes innovative compounds in three major oncology areas -- onco-inflammation, immuno-oncology and targeted therapies -- we believe Incyte is at the center of this transformation in cancer care.
Our lead JAK inhibitor, Jakafi® (ruxolitinib), is approved for use in patients with intermediate or high-risk myelofibrosis(1). We are also pursuing FDA approval in a second related myeloproliferative neoplasm, polycythemia vera. Further, we are evaluating JAK inhibitors in multiple new indications and in combinations targeting solid tumors such as pancreatic, breast, colorectal and non-small cell lung cancer.
We have established multiple collaborations with major pharmaceutical companies to support the clinical development and global commercialization of several of our compounds. Through strategic collaborations with Novartis and Eli Lilly, we are advancing the global development of two of our JAK1 and JAK2 inhibitor programs.
Our pipeline also includes a novel immunotherapy, an oral IDO1 inhibitor, which is being evaluated alone and through multiple clinical collaborations. We also have a selective targeted therapy, an oral PI3K-delta inhibitor, which is in clinical development as monotherapy and in combination with one of our JAK inhibitors.
Incyte is rooted in rigorous science, and our highly productive chemists and biologists are continuing to identify new molecules that support our goal to deliver first- and/or best-in-class medicines capable of making a difference in health care, improving the lives of patients, and building sustainable value for our shareholders.
Incyte's corporate headquarters are located in Wilmington, Delaware. For more information about Incyte, please see our Corporate Fact Sheet.
- About Incyte
- Jakafi® (ruxolitinib)
- Disease Education